Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Mack Roach MD
Closed to Accrual
Demonstrate that prophylactic neoadjuvant androgen deprivation therapy (NADT) and whole-pelvic radiation therapy (WPRT) will result in improvement in overall survival (OS) in patients with “unfavorable” intermediate risk or “favorable” high risk prostate cancer compared to NADT and high dose prostate and seminal vesicle (SV) radiation therapy (P + SV RT) using intensity modulated radiotherapy (IMRT) or EBRT with a high dose rate (HDR) or a permanent prostate (radioactive seed) implant (PPI) boost.
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website
Data for this trial is being collected via the NRG/RTOG Data Center.
Patients who are most likely to benefit from androgen deprivation therapy and whole-pelvic radiotherapy, defined as:
a) Having a significant risk of lymph node involvement (e.g. >15%, based on the Roach formula);
b) Being in one of the following risk groups:
GS 7-10 + T1c-T2b (palpation) + PSA < 50 ng/ml (includes intermediate and high risk patients);
GS 6 + T2c-T4 (palpation) + PSA < 50 ng/ml OR Gleason score 6 + ≥ 50% biopsies + PSA < 50 ng/ml;
GS 6 + T1c-T2b (palpation) + PSA > 20 ng/ml.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.